Journal Article

Efficacy and Safety of Niaoduqing Particles for Delaying Moderate-to-severe Renal Dysfunction： A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study

Ying Zheng;Guang-Yan Cai;Li-Qun He;Hong-Li Lin;Xiao-Hong Cheng;Nian-Song Wang;Gui-Hua Jian;Xu-Sheng Liu;Yu-Ning Liu;Zhao-Hui Ni;Jing-Ai Fang;Han-Lu Ding;Wang Guo;Ya-Ni He;Li-Hua Wang;Ya-Ping Wang;Hong-Tao Yang;Zhi-Ming Ye;Ren-Huan YU;Li-Juan Zhao;Wen-Hua Zhou;Wen-Ge Li;Hui-Juan Mao;Yong-Li Zhan;Zhao Hu;Chen Yao;Ri-Bao Wei;Xiang-Mei Chen

2017

Overview

Background： Chronic kidney disease （CKD） with moderate-to-severe renal dysfunction usually exhibits an irreversible course, and available treatments for delaying the progression to end-stage renal disease are limited. This study aimed to assess the efficacy and safety of the traditional Chinese medicine, Niaoduqing particles, for delaying renal dysfunction in patients with stage 3b-4 CKD.Methods： The present study was a prospective, randomized, double-blind, placebo-controlled, naulticentcr clinical trial. Frorn May 2013 to December 2013,300 CKD patients with an estimated glomerular filtration rate （eGFR） between 20 and 45 ml ＂rain ~＂ 1.73 m 2, aged 18-70 years were recruited from 22 hospitals in 11 Chinese provinces. Patients were randomized in a 1：1 ratio to either a test group, which was administered Niaoduqing particles 5 g thrice daily and 10 g before bedtime for 24 weeks, or a control group, which was administered a placebo using the same methods. The primary endpoints were changes in baseline serum creatinine （Scr） and eGFR after completion of treatment. The primary endpoints were analyzed using Student＇s t-test or Wilcoxon＇s rank-sum test. The present study reported results based on an intention-to-treat （ITT） analysis. Results： A total of 292 participants underwent the ITT analysis. At 24 weeks, the median （interquartile range） change in Scr was 1.1 （-13.0-24.1） and 11.7 （-2.6-42.9） p, mol/L for the test and control groups, respectively （Z = 2.642, P = 0.008）, and the median change in eGFR was -0.2 （-4.3-2.7） and -2.2 （-5.7-0.8） ml.min-1·1.73 m-2, respectively （Z = -2.408, P = 0.016）. There were no significant differences in adverse events between the groups. Conclusions： Niaoduqing particles safely and effectively delayed CKD progression in patients with stage 3b-4 CKD. This traditional Chinese medicine may be a promising alternative medication for patients with moderate-to-severe renal dysfunction.

• Publisher: Medknow Publications and Media Pvt. Ltd,Lippincott Williams & Wilkins Ovid Technologies,Department of Nephrology, Chinese People's Liberation Army General Hospital, Chinese People's Liberation Army Institute of Nephrology, State Key Laboratory of Kidney Diseases(2011DAV00088), National Clinical Research Center for Kidney Diseases, Beijing 100853, China%Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200021, China%Department of Nephrology, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, China%Department of Nephrology, Shaanxi Traditional Chinese Medicine Hospital, Xi'an, Shaanxi 710003, China%Department of Nephrology and Rheumatology, Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai 200233, China%Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong 510120, China%Department of Nephrology, Dongzhimen Hospital, The First Affiliated Hospital of Beijing University of Chinese Medicine, Beijing 100700, China%Department of Nephrology, Renji Hospital, Shanghai Jiao Tong University, Shanghai 200127, China%Department of Nephrology, First Affiliated Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China%Department of Nephrology, University of Electronic Science and Technology, Sichuan Academy of Sciences and Sichuan Provincial People's Hospital,Chengdu, Sichuan 610072, China%Department of Nephrology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China%Department of Nephrology, Daping Hospital, Third Military Medical University, Chongqing 400042, China%Department of Nephrology, Second Affiliated Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China%Department of Nephrology, Army General Hospital, Beijing 100700, China%Department of Nephrology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300192, China%Department of Nephrology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510030, China%Department of Nephrology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China%Department of Nephrology, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710032, China%Department of Nephrology, Second Hospital of Jilin University, Changchun, Jilin 130041, China%Department of Nephrology, China-Japan Friendship Hospital, Beijing 100029, China%Department of Nephrology, Jiangsu Province Hospital, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China%Department of Nephrology, Guang'anmen Hospital of China Academy of Traditional Chinese Medical Sciences, Beijing 100053, China%Department of Nephrology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China%Peking University Clinical Research Institute, Peking University, Beijing 100191, China,Medknow Publications & Media Pvt Ltd,Wolters Kluwer
• Subject: Analysis / Care and treatment / Chronic Kidney Disease; Moderate-to-severe Renal Dysfunction; Niaoduqing Particles; Randomized Controlled Trial; Traditional Chinese Medicine / Chronic kidney failure / Clinical trials / Consent / Double-blind studies / Hospitals / Kidney diseases / Laboratories / Nephrology / Original / Patients / Research centers / Researchers / Rheumatology / Risk factors / Rodents / Safety and security measures / Spleen / Substance abuse treatment / Traditional Chinese medicine / Urogenital system / 安全性 / 尿 / 延缓 / 疗效 / 肾功能不全 / 肾小球滤过率 / 随机 / 颗粒